BR112021018632A2 - Moléculas de ligação ao cd3 - Google Patents

Moléculas de ligação ao cd3

Info

Publication number
BR112021018632A2
BR112021018632A2 BR112021018632A BR112021018632A BR112021018632A2 BR 112021018632 A2 BR112021018632 A2 BR 112021018632A2 BR 112021018632 A BR112021018632 A BR 112021018632A BR 112021018632 A BR112021018632 A BR 112021018632A BR 112021018632 A2 BR112021018632 A2 BR 112021018632A2
Authority
BR
Brazil
Prior art keywords
binding
binding molecules
relates
antibody
cancer
Prior art date
Application number
BR112021018632A
Other languages
English (en)
Inventor
Fokko Van Loo Pieter
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of BR112021018632A2 publication Critical patent/BR112021018632A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

moléculas de ligação ao cd3. a invenção se refere a regiões variáveis de cadeia pesada, domínios de ligação e anticorpos específicos para proteínas de ligação cd3 e cd3 humanas. a invenção se refere adicionalmente ao uso de uma proteína de ligação ao cd3, de preferência, um anticorpo, da invenção no tratamento de câncer ou doença autoimune.
BR112021018632A 2019-03-29 2020-03-27 Moléculas de ligação ao cd3 BR112021018632A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166345 2019-03-29
EP19200931 2019-10-01
PCT/NL2020/050214 WO2020204708A1 (en) 2019-03-29 2020-03-27 Cd3 binding molecules

Publications (1)

Publication Number Publication Date
BR112021018632A2 true BR112021018632A2 (pt) 2021-11-23

Family

ID=70057206

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018632A BR112021018632A2 (pt) 2019-03-29 2020-03-27 Moléculas de ligação ao cd3

Country Status (12)

Country Link
US (1) US20220356251A1 (pt)
EP (1) EP3947456A1 (pt)
JP (2) JP2022527935A (pt)
KR (1) KR20210145136A (pt)
AU (1) AU2020254215A1 (pt)
BR (1) BR112021018632A2 (pt)
CA (1) CA3133624A1 (pt)
IL (1) IL286013A (pt)
MX (1) MX2021010877A (pt)
SG (1) SG11202109535SA (pt)
TW (1) TW202039578A (pt)
WO (1) WO2020204708A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4238992A1 (en) * 2022-03-01 2023-09-06 Technische Universität Darmstadt Two in one - antibodies binding to egfr/pd-l1-double positive cells
WO2023165813A1 (en) * 2022-03-01 2023-09-07 Technische Universität Darmstadt "two-in-one"-antibodies binding to egfr/pd-l1-double positive cells
US20240132615A1 (en) 2022-05-05 2024-04-25 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
NZ573132A (en) * 2006-06-06 2012-05-25 Glaxo Group Ltd Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
KR102261586B1 (ko) 2008-06-27 2021-06-08 메뤼스 엔.페. 항체 생산 비-인간 포유동물
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
CA2791109C (en) * 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PL2900694T3 (pl) 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
CA2991880A1 (en) * 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
EP3405490B1 (en) * 2016-01-21 2021-10-20 Pfizer Inc. Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
TW202003569A (zh) 2018-03-30 2020-01-16 荷蘭商美勒斯公司 多價抗體

Also Published As

Publication number Publication date
US20220356251A1 (en) 2022-11-10
JP2022527935A (ja) 2022-06-07
JP2023179541A (ja) 2023-12-19
WO2020204708A1 (en) 2020-10-08
IL286013A (en) 2021-10-31
EP3947456A1 (en) 2022-02-09
CA3133624A1 (en) 2020-10-08
AU2020254215A1 (en) 2021-09-30
MX2021010877A (es) 2021-10-22
SG11202109535SA (en) 2021-10-28
KR20210145136A (ko) 2021-12-01
TW202039578A (zh) 2020-11-01

Similar Documents

Publication Publication Date Title
BR112021018632A2 (pt) Moléculas de ligação ao cd3
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
PH12019500545A1 (en) Cd3 binding antibodies
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA202092847A1 (ru) Антитела к cd3 и их применение
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
BRPI0513078B8 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
DE602006013029D1 (de) Anti-egfr-antikörper
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
WO2020128446A3 (en) Anti-btla antibodies
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
CO2021000497A2 (es) Proteína de unión al antígeno anti-steap1
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
CO2023001559A2 (es) Anticuerpos fgfr3 y métodos de uso
EA202192124A1 (ru) Cd3-связывающие молекулы